• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The first international guidance on antithrombotic therapy in the elderly came from the
European Society of Cardiology Working Group on Thrombosis in 2015. This same group …

Background In randomised controlled trials, fixed-dose combination treatments (or polypills)
have been shown to reduce a composite of cardiovascular disease outcomes in primary …

Background A fixed-dose combination therapy (polypill strategy) has been proposed as an
approach to reduce the burden of cardiovascular disease, especially in low-income and …

Background: Single-pill combination improves adherence and persistence to medication in
hypertension. It remains unclear whether this also reduces cardiovascular outcomes and all …

By the end of 2020, more than 19 million Americans had received the diagnosis of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 1 Although a substantial …

Background To evaluate the effectiveness of a cardiovascular polypill including aspirin,
ramipril and atorvastatin (CNIC-Polypill), on the incidence of recurrent major cardiovascular …

Prior studies have reported improvements in population-level risk factor burden and
cardiovascular disease (CVD) outcomes using polypills for CVD risk reduction. However, a …

Importance Aspirin is an effective and low-cost option for reducing atherosclerotic
cardiovascular disease (CVD) events and improving mortality rates among individuals with …

Polypills have been approved in more than 30 countries, but worldwide experience with and
availability of polypills remain limited, unlike fixed-dose combinations in other diseases such …